Fièvre hémorragique à virus Ebola : Questions médicales fréquentes
Nom anglais: Hemorrhagic Fever, Ebola
Descriptor UI:D019142
Tree Number:C01.925.782.580.250.400
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Fièvre hémorragique à virus Ebola : Questions médicales les plus fréquentes",
"headline": "Fièvre hémorragique à virus Ebola : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Fièvre hémorragique à virus Ebola : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-01",
"dateModified": "2026-04-21",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Fièvre hémorragique à virus Ebola"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Infections à Filoviridae",
"url": "https://questionsmedicales.fr/mesh/D018702",
"about": {
"@type": "MedicalCondition",
"name": "Infections à Filoviridae",
"code": {
"@type": "MedicalCode",
"code": "D018702",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C01.925.782.580.250"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Fièvre hémorragique à virus Ebola",
"alternateName": "Hemorrhagic Fever, Ebola",
"code": {
"@type": "MedicalCode",
"code": "D019142",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "John S Schieffelin",
"url": "https://questionsmedicales.fr/author/John%20S%20Schieffelin",
"affiliation": {
"@type": "Organization",
"name": "Sections of Infectious Disease, Departments of Pediatrics and Internal Medicine, School of Medicine, Tulane University, New Orleans, LA, USA."
}
},
{
"@type": "Person",
"name": "Masayuki Saijo",
"url": "https://questionsmedicales.fr/author/Masayuki%20Saijo",
"affiliation": {
"@type": "Organization",
"name": "Sapporo City Public Health Office."
}
},
{
"@type": "Person",
"name": "Samuel C Ficenec",
"url": "https://questionsmedicales.fr/author/Samuel%20C%20Ficenec",
"affiliation": {
"@type": "Organization",
"name": "Tulane University School of Medicine, New Orleans, Louisiana."
}
},
{
"@type": "Person",
"name": "Susan D Emmett",
"url": "https://questionsmedicales.fr/author/Susan%20D%20Emmett",
"affiliation": {
"@type": "Organization",
"name": "Center for Health Policy and Inequalities Research, Duke University, Durham, North Carolina."
}
},
{
"@type": "Person",
"name": "David W Hawman",
"url": "https://questionsmedicales.fr/author/David%20W%20Hawman",
"affiliation": {
"@type": "Organization",
"name": "Laboratory of Virology, Rocky Mountain Laboratories, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Spatial and functional arrangement of Ebola virus polymerase inside phase-separated viral factories.",
"datePublished": "2023-07-13",
"url": "https://questionsmedicales.fr/article/37443171",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41467-023-39821-7"
}
},
{
"@type": "ScholarlyArticle",
"name": "In silico exploration of deep-sea fungal metabolites as inhibitor of Ebola and Marburg VP35 and VP40.",
"datePublished": "2024-07-25",
"url": "https://questionsmedicales.fr/article/39052567",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0307579"
}
},
{
"@type": "ScholarlyArticle",
"name": "Impact of Ebola virus nucleoprotein on VP40 virus-like particle production: a computational approach.",
"datePublished": "2024-05-25",
"url": "https://questionsmedicales.fr/article/38796621",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s42003-024-06300-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mpox in East Africa: Learning from COVID-19 and Ebola to Strengthen Public Health Responses.",
"datePublished": "2024-10-08",
"url": "https://questionsmedicales.fr/article/39459912",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/v16101578"
}
},
{
"@type": "ScholarlyArticle",
"name": "A novel indicator in epidemic monitoring through a case study of Ebola in West Africa (2014-2016).",
"datePublished": "2024-05-27",
"url": "https://questionsmedicales.fr/article/38802461",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-62719-3"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Infection",
"item": "https://questionsmedicales.fr/mesh/D007239"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies virales",
"item": "https://questionsmedicales.fr/mesh/D014777"
},
{
"@type": "ListItem",
"position": 4,
"name": "Infections à virus à ARN",
"item": "https://questionsmedicales.fr/mesh/D012327"
},
{
"@type": "ListItem",
"position": 5,
"name": "Infections à Mononegavirales",
"item": "https://questionsmedicales.fr/mesh/D018701"
},
{
"@type": "ListItem",
"position": 6,
"name": "Infections à Filoviridae",
"item": "https://questionsmedicales.fr/mesh/D018702"
},
{
"@type": "ListItem",
"position": 7,
"name": "Fièvre hémorragique à virus Ebola",
"item": "https://questionsmedicales.fr/mesh/D019142"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Fièvre hémorragique à virus Ebola - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Fièvre hémorragique à virus Ebola",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-04-29",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Fièvre hémorragique à virus Ebola",
"description": "Comment diagnostique-t-on la fièvre Ebola ?\nQuels sont les tests utilisés pour Ebola ?\nQuand doit-on suspecter Ebola ?\nLes tests de laboratoire sont-ils fiables ?\nPeut-on diagnostiquer Ebola par des symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D019142?page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Fièvre hémorragique à virus Ebola",
"description": "Quels sont les symptômes de la fièvre Ebola ?\nLa fièvre est-elle un symptôme précoce ?\nLes hémorragies sont-elles fréquentes ?\nY a-t-il des symptômes neurologiques ?\nLes symptômes apparaissent-ils rapidement ?",
"url": "https://questionsmedicales.fr/mesh/D019142?page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Fièvre hémorragique à virus Ebola",
"description": "Comment prévenir l'infection par Ebola ?\nLe port de gants est-il nécessaire ?\nLes vaccinations sont-elles recommandées ?\nComment gérer les déchets médicaux ?\nLes voyages en zone d'épidémie sont-ils sûrs ?",
"url": "https://questionsmedicales.fr/mesh/D019142?page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Fièvre hémorragique à virus Ebola",
"description": "Quel est le traitement principal pour Ebola ?\nLes antiviraux sont-ils efficaces contre Ebola ?\nComment gérer la déshydratation ?\nLes transfusions sanguines sont-elles utiles ?\nY a-t-il un vaccin contre Ebola ?",
"url": "https://questionsmedicales.fr/mesh/D019142?page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Fièvre hémorragique à virus Ebola",
"description": "Quelles sont les complications possibles d'Ebola ?\nL'infection peut-elle causer des séquelles ?\nLes complications sont-elles fréquentes ?\nComment les complications sont-elles gérées ?\nLes complications peuvent-elles être mortelles ?",
"url": "https://questionsmedicales.fr/mesh/D019142?page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Fièvre hémorragique à virus Ebola",
"description": "Qui est le plus à risque d'Ebola ?\nLes voyageurs sont-ils à risque ?\nLes personnes ayant des antécédents médicaux sont-elles plus vulnérables ?\nLes enfants sont-ils plus à risque ?\nLes contacts avec des animaux sont-ils un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D019142?page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on la fièvre Ebola ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests PCR, des tests sérologiques et l'historique d'exposition."
}
},
{
"@type": "Question",
"name": "Quels sont les tests utilisés pour Ebola ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests PCR et les tests ELISA sont couramment utilisés pour détecter le virus."
}
},
{
"@type": "Question",
"name": "Quand doit-on suspecter Ebola ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "En cas de symptômes compatibles et d'exposition récente à une zone d'épidémie."
}
},
{
"@type": "Question",
"name": "Les tests de laboratoire sont-ils fiables ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests PCR sont très sensibles et spécifiques pour le virus Ebola."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer Ebola par des symptômes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent indiquer Ebola, mais un test de laboratoire est nécessaire pour confirmer."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes de la fièvre Ebola ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Fièvre, douleurs musculaires, fatigue, vomissements, diarrhée, et hémorragies."
}
},
{
"@type": "Question",
"name": "La fièvre est-elle un symptôme précoce ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la fièvre est souvent l'un des premiers symptômes de l'infection par Ebola."
}
},
{
"@type": "Question",
"name": "Les hémorragies sont-elles fréquentes ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les hémorragies peuvent survenir, mais elles ne sont pas présentes chez tous les patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes neurologiques peuvent apparaître, comme la confusion ou des convulsions."
}
},
{
"@type": "Question",
"name": "Les symptômes apparaissent-ils rapidement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent apparaître entre 2 et 21 jours après l'exposition au virus."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'infection par Ebola ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Éviter le contact avec des personnes infectées et pratiquer une bonne hygiène."
}
},
{
"@type": "Question",
"name": "Le port de gants est-il nécessaire ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le port de gants et d'équipements de protection est essentiel lors de soins aux malades."
}
},
{
"@type": "Question",
"name": "Les vaccinations sont-elles recommandées ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vaccination est recommandée pour les travailleurs de la santé dans les zones à risque."
}
},
{
"@type": "Question",
"name": "Comment gérer les déchets médicaux ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les déchets doivent être traités comme des déchets infectieux pour éviter la contamination."
}
},
{
"@type": "Question",
"name": "Les voyages en zone d'épidémie sont-ils sûrs ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est conseillé d'éviter les voyages dans les zones d'épidémie d'Ebola sans précautions."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal pour Ebola ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement spécifique, mais des soins de soutien sont essentiels."
}
},
{
"@type": "Question",
"name": "Les antiviraux sont-ils efficaces contre Ebola ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antiviraux comme le remdesivir montrent des résultats prometteurs, mais ne sont pas standard."
}
},
{
"@type": "Question",
"name": "Comment gérer la déshydratation ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hydratation par voie intraveineuse est cruciale pour traiter la déshydratation sévère."
}
},
{
"@type": "Question",
"name": "Les transfusions sanguines sont-elles utiles ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les transfusions de plasma convalescent peuvent aider, mais leur efficacité varie."
}
},
{
"@type": "Question",
"name": "Y a-t-il un vaccin contre Ebola ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le vaccin rVSV-ZEBOV est utilisé pour prévenir l'infection par le virus Ebola."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles d'Ebola ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des défaillances organiques, des hémorragies et des infections secondaires."
}
},
{
"@type": "Question",
"name": "L'infection peut-elle causer des séquelles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains survivants peuvent avoir des séquelles neurologiques ou oculaires."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications graves surviennent chez une proportion significative des patients infectés."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications nécessitent des soins intensifs et un suivi médical rigoureux."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être mortelles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent entraîner la mort, surtout sans traitement approprié."
}
},
{
"@type": "Question",
"name": "Qui est le plus à risque d'Ebola ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs de la santé et les personnes en contact avec des malades sont les plus à risque."
}
},
{
"@type": "Question",
"name": "Les voyageurs sont-ils à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les voyageurs dans des zones d'épidémie sans précautions sont à risque d'infection."
}
},
{
"@type": "Question",
"name": "Les personnes ayant des antécédents médicaux sont-elles plus vulnérables ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes immunodéprimées peuvent avoir un risque accru de complications graves."
}
},
{
"@type": "Question",
"name": "Les enfants sont-ils plus à risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les enfants peuvent être plus vulnérables en raison de leur système immunitaire immature."
}
},
{
"@type": "Question",
"name": "Les contacts avec des animaux sont-ils un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le contact avec des animaux sauvages infectés peut être un facteur de risque d'infection."
}
}
]
}
]
}
Ebola virus (EBOV) infection induces the formation of membrane-less, cytoplasmic compartments termed viral factories, in which multiple viral proteins gather and coordinate viral transcription, replic...
VP30 and VP40 proteins of Ebola and Marburg viruses have been recognized as potential targets for antiviral drug development due to their essential roles in the viral lifecycle. Targeting these protei...
Ebola virus (EBOV) matrix protein VP40 can assemble and bud as virus-like particles (VLPs) when expressed alone in mammalian cells. Nucleoprotein (NP) could be recruited to VLPs as inclusion body (IB)...
The Africa Centers for Disease Control and Prevention declared mpox a Public Health Emergency of Continental Security (PHECS) in Africa. African public health systems have moved to mobilize a response...
The E/S (exposed/susceptible) ratio is analyzed in the SEIR model. The ratio plays a key role in understanding epidemic dynamics during the 2014-2016 Ebola outbreak in Sierra Leone and Guinea. The max...
The rVSVDG-ZEBOV-GP (Ervebo®) vaccine is both immunogenic and protective against Ebola. However, the vaccine can cause a broad range of transient adverse reactions, from headache to arthritis. Identif...
In this study, we developed a machine learning approach to integrate prevaccination gene expression data with adverse events that occurred within 14 days post-vaccination....
We analyzed the expression of 144 genes across 343 blood samples collected from participants of 4 phase I clinical trial cohorts: Switzerland, USA, Gabon, and Kenya. Our machine learning approach reve...
In September 2022, a new Ebola outbreak was reported in Uganda, East Africa, and 142 confirmed cases, including 19 Healthcare workers (HCWs) reported. Ebola is not endemic in Somalia, but the country ...
An online self-administrated cross-sectional survey was conducted among HCWs (n = 1103) in all six federal member states of Somalia using a validated, reliable, well-structured questionnaire. Data we ...
Over one-third (37.3%) of HCWs had poor Knowledge; the mean knowledge score was 7.97 SD ± 2.15. Almost 40.1% of the HCWs had a negative attitude; the mean attitude was 27.81 SD ± 8.06. Low-income HCWs...
Most Somali healthcare workers showed good Knowledge and a positive attitude toward the Ebola virus. The implementation to enhance Knowledge and attitude must specifically focus on low-income HCWs, Mi...
Intraventricular hemorrhage (IVH) is a type of ventricular bleeding that results in significant morbidity and mortality. Multiple studies have investigated the use of urokinase in IVH treatment. The u...
In total, 94 adult patients with hypertensive intracerebral hemorrhage with ventricular extension or primary IVH were enrolled between 2015 and 2021. Participants were categorized into two groups: "EV...
There were no significant differences in the reduction rate of mGRAEB scores within a 7-day period (-50.0 [-64.4 to -32.5] % vs -44.2 [-59.3 to -7.9] %; p = 0.489). In addition, investigation of the t...
This study found that intraventricular urokinase use in patients with IVH was not associated with reduced IVH severity. In addition, urokinase use was not associated with better functional outcomes or...
Emerging infectious diseases like the Ebola Virus Disease (EVD) pose significant global public health threats. Uganda has experienced multiple EVD outbreaks, the latest occurring in 2022. Frontline he...
This multicentre nationwide cross-sectional study was conducted from July to September 2023 among HCWs providing emergency care in 14 secondary and tertiary hospitals across Uganda. Participants were ...
Data from 691 eligible HCWs with a median age of 32 (IQR: 28-38) was analyzed (response rate: 92%). Only one-third (34.4%, n = 238) had received EVD training in the past year. The median EVD knowledge...
Our study shows that the readiness of HCWs in Uganda to respond to EVD outbreaks varies by individual factors and information sources. We recommend targeted training and suggest future research on edu...
In the immediate aftermath of a 14-year civil conflict that disrupted the health system, Liberia adopted the internationally recommended integrated disease surveillance and response (IDSR) strategy in...
We reviewed 112 official Government documents and peer-reviewed articles and conducted 29 in-depth interviews with key informants from December 2021 to March 2022 to gain perspectives on IDSR in the p...
Despite the adoption of the IDSR framework, Liberia failed to secure the resources-human, logistical, and financial-to support effective implementation over the 10-year period. Documents and interview...
Our findings suggest that post-war, Liberia's health system intended to prioritize epidemic preparedness and response with the adoption of IDSR. However, insufficient investment and systems developmen...